Transcatheter Tricuspid Valve Implantation of NaviGate Bioprosthesis in a Preclinical Model

Autor: Samir R. Kapadia, R. Nair, Cristian Baeza, Krzysztof Bartuś, Cesare Beghi, Josep Rodés-Cabau, R. C. Quijano, Haytham Elgharably, Jose L. Navia, Gabriel Maluenda
Jazyk: angličtina
Rok vydání: 2018
Předmět:
medicine.medical_specialty
Beating heart
lcsh:Diseases of the circulatory (Cardiovascular) system
TR
tricuspid regurgitation
medicine.medical_treatment
RA
right atrium
RVOT
right ventricle outflow
Hemodynamics
Regurgitation (circulation)
030204 cardiovascular system & hematology
tricuspid valve
03 medical and health sciences
PRECLINICAL RESEARCH
ICE
intracardiac echocardiography
0302 clinical medicine
Right heart failure
Internal medicine
RV
right ventricle/ventricular
medicine
030212 general & internal medicine
cardiovascular diseases
transcatheter replacement
preclinical model
Tricuspid valve
RHF
right heart failure
Ventricular function
business.industry
PVL
paravalvular leak
Stent
Alternative treatment
medicine.anatomical_structure
lcsh:RC666-701
Cardiology
cardiovascular system
TV
tricuspid valve
TA
tricuspid annulus
NaviGate bioprosthesis
Cardiology and Cardiovascular Medicine
business
Zdroj: JACC: Basic to Translational Science, Vol 3, Iss 1, Pp 67-79 (2018)
JACC: Basic to Translational Science
Popis: Visual Abstract
Highlights • Surgery for isolated tricuspid regurgitation carries a high mortality risk, especially in the setting of right ventricular dysfunction and reoperation. • Transcatheter valve therapy is as promising alternative for treatment of isolated tricuspid valve disease associated with right heart failure. • The NaviGate bioprosthesis is a novel self-expanding valved stent designed to treat functional tricuspid regurgitation. • The preclinical evaluation shows that transcatheter tricuspid valve implantation using the NaviGate device is safe, is feasible through 2 different approaches, and results in a secure and stable engagement of the native annulus, with excellent hemodynamic and valve performance.
Summary Patients with isolated functional or recurrent tricuspid regurgitation are often denied surgery because they are considered to be at high risk. Transcatheter valve therapy provides a less invasive alternative for tricuspid regurgitation associated with right heart failure. We have evaluated the feasibility of transcatheter tricuspid valve implantation of the NaviGate valved stent in a long-term swine model. The valved stent was successfully implanted through transjugular and transatrial approaches on the beating heart with excellent hemodynamic and valve performance. No conduction disturbance or coronary obstruction was observed. This technology could provide an alternative treatment for patients who are at high surgical risk with severe tricuspid regurgitation and compromised right ventricular function.
Databáze: OpenAIRE
Externí odkaz: